Edition:
United Kingdom

Omeros Corp (OMER.OQ)

OMER.OQ on NASDAQ Stock Exchange Global Market

14.35USD
24 Apr 2018
Change (% chg)

-- (--)
Prev Close
$14.35
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
319,894
52-wk High
$27.07
52-wk Low
$8.36

Select another date:

Wed, Apr 11 2018

BRIEF-Omeros Announces Amendment Of Credit Facility

* AMENDED ITS EXISTING CREDIT FACILITY WITH CERTAIN AFFILIATES OF CRG LP

BRIEF-Omeros Q4 Loss Per Share $0.34

* Q4 REVENUE $13.8 MILLION Source text for Eikon: Further company coverage:

BRIEF-European Medicines Agency Issues Orphan Drug Designation Positive Opinion for Omeros' OMS721

* EUROPEAN MEDICINES AGENCY ISSUES ORPHAN DRUG DESIGNATION POSITIVE OPINION FOR OMEROS’ OMS721 IN THE TREATMENT OF IGA NEPHROPATHY

BRIEF-Omeros Reaches Agreement With FDA On OMS721 Phase 3 Trial Protocol For IgA Nephropathy

* OMEROS CORPORATION REACHES AGREEMENT WITH FDA ON OMS721 PHASE 3 TRIAL PROTOCOL FOR IGA NEPHROPATHY

BRIEF-Omeros Corporation Announces Fda Approval Of Omidria For Use In Pediatric Patients

* OMEROS CORPORATION ANNOUNCES FDA APPROVAL OF OMIDRIA® FOR USE IN PEDIATRIC PATIENTS

BRIEF-Omeros Corp reports Q3 loss per share $0.16

* Omeros Corporation reports third quarter 2017 financial results

BRIEF-OMEROS REPORTS ADDITIONAL POSITIVE DATA FOR OMS721

* OMEROS REPORTS ADDITIONAL AND CONSISTENTLY POSITIVE DATA FOR OMS721 IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY

Select another date: